AdhexPharma
AdhexPharma is an independent contract development and manufacturing organization (CDMO) specializing in oral films and transdermal or topical patches for drug delivery. The company provides comprehensive end-to-end services from feasibility studies and formulation to analytical development, clinical batch production, and commercial manufacturing under cGMP. With expertise in complex dosage forms, handling potent APIs, and meeting global regulatory requirements, AdhexPharma integrates sustainable practices and operates advanced facilities in France and Germany, supporting both large pharmaceutical firms and biotech innovators worldwide.
What We Do
Oral films, including orodispersible formats, designed for fast-dissolving, buccal, or sublingual administration. Provide customized drug release and support for complex APIs.
Adhesive patch technologies for controlled, continuous transdermal drug delivery across multiple therapeutic areas such as pain management, hormone replacement, nicotine replacement, cardiovascular conditions, and mental health.
Product development from feasibility studies through formulation optimization, process scale-up, technology transfer, and preparation of validation batches for oral film and patch drug delivery systems.
Manufacturing of oral films and patches under cGMP, EMA, and FDA-compliant conditions from pilot to full commercial scale, including handling of high-potency APIs and hormones.
Development, validation, and transfer of analytical methods; routine quality control; ICH-compliant stability studies; and specific analytics for transdermal and oral film dosage forms.
Licensing agreements for market-ready drug delivery products in oral film and transdermal patch formats, enabling rapid partner commercialization.
Battlefield Resuscitation
Psychological and Cognitive Health and Performance
Regenerative Medicine
Key People
Founder and President
Managing Director
Human Resources Director
Site Director
Laboratory Director
CMC Development Director
News & Updates
Included among Europe’s top 300 long-term growth champions, reflecting exceptional sales growth and resilience.
Overview of expertise in API integration for customizable oral film and transdermal patch drug delivery platforms.
Announcement of a new 8,000 m² advanced pharmaceutical facility featuring expanded production, storage, and laboratory capacity, with focus on sustainability.
Discussion of the therapeutic versatility and patient benefits of transdermal patch drug delivery systems in pain management, hormone therapy, smoking cessation, cardiovascular, and mental health.
Recognition as one of the fastest-growing companies in Europe, ranking 157th overall and 8th in Healthcare & Life Sciences.
Company ranked 171st in the Financial Times' Long-Term Growth Champions and 6th in Pharmaceuticals & Cosmetics.